Any current/future new fundraising through debt or equity?

No explicit mention of current or future fundraising through debt or equity was made in the transcript. A INR 50 crore loan facility was approved for Dhanuka Laboratories, but it is indicated as an approval for occasional use rather than a new fundraising. Discussions around capex for the Dahej plant indicate plans for fresh capital expenditure based on R&D product development but no mention of specific fundraising methods. The company is focusing on internal cash deployment for investments, buybacks, and dividends, maintaining cash at a similar level in recent years. No announcements or indic

Any current/future capex/capital investment/strategic investment?

The Dahej plant has 2 phases of capex planned; the second phase may start next year or in 2026. The company will not wait for international CDMO collaboration projects to begin fresh capex; instead, new products from R&D reaching maturity will trigger fresh investments, possibly starting next FY. The current Dahej plant can add 2-3 more products and is multipurpose with capacity to manufacture 4-5 products simultaneously. Fresh capex depends on the pace of product development in R&D. The company is actively working on new technical products including bifenthrin and expects to increase revenue

Future growth expectations in sales/revenue/volumes?

New product introductions are expected to drive future growth, with revenue from new products forecasted to exceed 20-25% by FY '25-'26. Volume growth in Q2 was strong at 20%, with H1 volume growth around 10%; momentum is expected to continue into H2. There is confidence in sustaining top-line growth and improving EBITDA margins by approximately 200 basis points by year-end due to product mix and margin improvements. The Rabi season, especially in South and East India, offers strong opportunities for key products like Defend, Decide, Mesotrax, and Implode. Maize and chilli markets are

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects new product revenues to increase substantially, potentially crossing 25% of total revenue by FY '25/'26, contingent on decent rainfall. Volume growth was strong at 20% in Q2, with consistent focus on innovative products contributing to margin improvement. Gross margin expansion is projected, driven by product mix and inventory normalization, with an anticipated 200 basis points margin improvement by year-end. Fresh capital expenditure is planned in the next financial year, aligned with new product development and R&D progress. Confident outlook for strong performanc

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Dhanuka Agritech Limited. However, it highlights that the company has several products in its development pipeline and plans for fresh capex depending on R&D progress (Page 17). The company is working closely on drone technology with a partner company, indicating potential future collaboration but no specific orderbook info (Page 17). Discussions around sales show good volume growth (20% in Q2) and clean channel inventory with stocks aligned to consumption, implying a stable order flow but no de

Dhanuka Agritech LtdQ2 FY24Fertilizers & Agrochemicals

Dhanuka Agritech Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹868.5P/E: 14.4Market Cap: ₹3.9K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

New product introductions are expected to drive future growth, with revenue from new products forecasted to exceed 20-25% by FY '25-'26.
Volume growth in Q2 was strong at 20%, with H1 volume growth around 10%; momentum is expected to continue into H2.
There is confidence in sustaining top-line growth and improving EBITDA margins by approximately 200 basis points by year-end due to product mix and margin improvements.
The Rabi season, especially in South and East India, offers strong opportunities for key products like Defend, Decide, Mesotrax, and Implode.
Maize and chilli markets are growing, with maize herbicides and insecticides targeting high-value crops offering large upside.
Capacity is sufficient to almost double revenue with current formulation capacity without immediate capex.
Fresh capex for additional products will depend on R&D product pipeline maturity, expected possibly from next financial year.

Margin guidance

Category 1

The company expects new product revenues to increase substantially, potentially crossing 25% of total revenue by FY '25/'26, contingent on decent rainfall.
Volume growth was strong at 20% in Q2, with consistent focus on innovative products contributing to margin improvement.
Gross margin expansion is projected, driven by product mix and inventory normalization, with an anticipated 200 basis points margin improvement by year-end.
Fresh capital expenditure is planned in the next financial year, aligned with new product development and R&D progress.
Confident outlook for strong performance in H2 FY '24 due to key products like Decide, Defend, Implode, and Mesotrax gaining traction, especially in crops like maize, chilli, and paddy.
EBITDA margin guidance remains positive with expected incremental margin improvement of around 150-200 basis points.
The company aims to deliver around INR 100 crore revenue from bifenthrin in FY '25.

See what Dhanuka Agritech Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of current or future fundraising through debt or equity was made in the transcript.
A INR 50 crore loan facility was approved for Dhanuka Laboratories, but it is indicated as an approval for occasional use rather than a new fundraising.
Discussions around capex for the Dahej plant indicate plans for fresh capital expenditure based on R&D product development but no mention of specific fundraising methods.
The company is focusing on internal cash deployment for investments, buybacks, and dividends, maintaining cash at a similar level in recent years.
No announcements or indications were provided regarding raising equity or additional debt fundraising in the near term.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Dhanuka Agritech Limited.
However, it highlights that the company has several products in its development pipeline and plans for fresh capex depending on R&D progress (Page 17).
The company is working closely on drone technology with a partner company, indicating potential future collaboration but no specific orderbook info (Page 17).
Discussions around sales show good volume growth (20% in Q2) and clean channel inventory with stocks aligned to consumption, implying a stable order flow but no detailed pending order data (Pages 12,13).
Overall, no direct quantitative details on order book or pending orders were disclosed in the call transcript provided.

See what Dhanuka Agritech Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The Dahej plant has 2 phases of capex planned; the second phase may start next year or in 2026.
The company will not wait for international CDMO collaboration projects to begin fresh capex; instead, new products from R&D reaching maturity will trigger fresh investments, possibly starting next FY.
The current Dahej plant can add 2-3 more products and is multipurpose with capacity to manufacture 4-5 products simultaneously.
Fresh capex depends on the pace of product development in R&D.
The company is actively working on new technical products including bifenthrin and expects to increase revenue from these products.
There is an ongoing loan facility of around INR 50 crores for Dhanuka Laboratories, already approved for operational needs.
No current product revenue from Dahej plant as of Q2, but cost impact was around INR 5-6 crores.

Track Dhanuka Agritech Ltd — get its next earnings analysis in your feed

How does Dhanuka Agritech Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisDhanuka Agritech Ltd

Rev 3Mar 1

See where Dhanuka Agritech Ltd sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Dhanuka Agritech Ltd rank in Fertilizers & Agrochemicals?

Compare Dhanuka Agritech Ltd against every Fertilizers & Agrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Dhanuka Agritech Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Bhagiradha Chemicals & Industries Ltd (Q2 FY26)
140.1 crore, up 35% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q2 FY26 investor presentation — and how it ran
Bhagiradha Chemicals & Industries Ltd (Q3 FY26)
114.0 crore, up 11% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q3 FY26 investor presentation — and how it ran
Advance Agrolife Ltd (Q3 FY26)
Q3 FY26 revenue from operations was ₹1,338 million, up 18% year-on-year (YoY) from ₹1,134 million in Q3 FY25 (Pages 23-24). Key investor presentation takeaways
Dhansa Labs Ltd (Q4 FY26)
120-140 crores in additional annual revenue upon stabilization, with initial revenue of around Rs. Key concall takeaways from Dhansa Labs's Q4 FY26 earnings…

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs Sumitomo Chemical India Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →